From Geert: “Can anyone explain how the updated, Omicron-adapted booster could induce functional Abs against Omicron-derived spike protein in a previously C-19 vaccinated population (i.e., the bulk of the target population for this new vaccine!) when even the wild virus (i.e., the circulating [sub]variants) is unable to do so?”
From Geert: “I don’t think the problem comes from potential spillback from new animal reservoirs into humans - as the authors seem to suggest - but exactly the other way around. Highly vaccinated human populations, but not animals, are currently driving the propagation of more infectious and more virulent SC-2 -immune escape variants. It is anything but unlikely that these more infectious and more virulent variants could soon unleash a pandemic in animal populations with weakened innate immunity. Our livestock kept in highly populated industrial farms (cattle, pigs, poultry) is certainly at risk because high population density causes stress, which negatively impacts on innate immunity. This – together with the short life cycle of livestock- negatively impacts on herd immunity! “
'I'm sorry - he's not able to come in unless he has his mask on,' says Michelle Williams, the school principal. 'I welcome him here, and I've said this before and I'll say it again: I want him here, but it is our district's policy that students have to wear a mask.'
“Just as we are dealing with the probable emergence of fourth wave of COVID-19, a new virus known as tomato flu, or tomato fever, has emerged in India in the state of Kerala in children younger than 5 years. The rare viral infection is in an endemic state and is considered non-life-threatening; however, because of the dreadful experience of the COVID-19 pandemic, the vigilant management is desirable to prevent further outbreaks.”
"We have known from the beginning that this vaccine would not be a silver bullet, that it would not meet all the expectations that are being put on it and that we don't have firm efficacy data or effectiveness data in this context.”
“Paxlovid will remain important for people at the highest risk of severe COVID-19, such as seniors and those with compromised immune systems,” said Dr. David Boulware, a University of Minnesota researcher and physician, who was not involved in the study. “But for the vast majority of Americans who are now eligible, this really doesn’t have a lot of benefit.”
A group of independent German scientists found toxic components—mostly metallic—in all the COVID vaccine samples they analyzed, “without exception” using modern medical and physical measuring techniques. The Working Group for COVID Vaccine Analysis says that some of the toxic elements found inside the AstraZeneca, Pfizer, and Moderna vaccine vials were not listed in the ingredient lists from the manufacturers.
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.